Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

25 Sep 2023

TheraPsil Unveils MDMA-Assisted Psychotherapy Training Program

Non-profit TheraPsil announces launching of MDMA therapy training program....

By Microdose NewsDesk

Industry

22 Sep 2023

Cybin Completes Phase 2 Enrollment of CYB003 for Major Depressive Disorder

Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder....

By Microdose NewsDesk

Industry

21 Sep 2023

Seelos Therapeutics Announces Results from Phase II Depression Trial

Seelos Therapeutics has released results from its SLS-002 Phase II study of adults with Major Depressive Disorder at Imminent Risk of Suicide....

By Microdose NewsDesk

Industry

20 Sep 2023

Numinus Closes Bioscience Lab and Consolidates Clinics

Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

news

Don’t Miss

18 Sep 2023

News You Might Have Missed: Sep 18th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Finance

15 Sep 2023

Beckley Waves Raises $3.3 Million Funding Round

Beckley Waves raises $3.3 million, capital to be used for investing in startups focused on infrastructure and services for psychedelic therapies....

By Microdose NewsDesk
maps

Industry

14 Sep 2023

MAPS Publishes Results of Successful Phase 3 Trial

In big industry news, MAPS has published the second part of its long-awaited Phase 3 trial of MDMA-assisted therapy for PTSD....

By Microdose NewsDesk
Mindmed trial

Industry

12 Sep 2023

MindMed Completes Dosing of Phase 2b Trial

MindMed has completed dosing of its main Phase 2b clinical trial. The study — investigating LSD for Generalized Anxiety Disorder (GAD) — has dosed 198 participants across 20 clinical sites....

By Microdose NewsDesk

Industry

11 Sep 2023

PurMinds Appoints Leading Drug Designer to Scientific Advisory Board

Dr. Kozikowski is a leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience....

By Microdose NewsDesk

Follow us on social

Latest News

Medical Psilocybin Act

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

You Might Also Like

9 Feb 2026

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

For much of the last decade, psychedelic medicine has been driven by clinical outcomes first and mechanistic explanations second. Promising results in depression, anxiety, and trauma propelled compounds like psilocybin...

By Madison Roberts

19 Jan 2026

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics....

By Madison Roberts

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.